What a Good Quality Agreement Actually Covers
And Why It Matters Before You Need It
Every biotech company that works with a contract manufacturer has a quality agreement on file. It's a regulatory expectation. It gets signed before work begins. And then, in a surprising number of cases, it gets filed away and never looked at again until something goes wrong.
That's a problem. Because the quality agreement isn't just a legal document. It's the operational foundation of your CMO relationship. When it's done well, it's the thing that keeps both parties aligned on who's responsible for what, how issues get handled, and what the expectations are on both sides. When it's treated as a formality, it leaves gaps that only become visible during a deviation, a failed batch, or a regulatory inspection.
I've seen both versions play out, and the difference between a quality agreement that protects you and one that just checks a box is significant.
It's an Operational Document, Not a Legal One
The most common mistake I see is treating the quality agreement as something that lives with legal and quality, gets negotiated once, signed, and shelved. When it's approached that way, the people who actually manage the CMO relationship day to day often haven't read it closely enough to know what it says. And the people who wrote it may not have had enough operational context to anticipate where the real friction points would be.
A good quality agreement is written with the assumption that things will go wrong, because they will. It should be clear enough that when a deviation occurs at your CMO, neither side has to debate who owns the investigation, who approves the corrective action, and what the timeline expectations are. When a batch fails, the quality agreement should already define how that gets communicated, how quickly, and to whom. When a change is proposed to the manufacturing process, it should be clear what requires your approval and what your CMO can execute independently.
If your quality agreement doesn't answer those questions with specificity, it's not doing its job. And you won't find that out until you're in the middle of a situation where you really need it to.
What Good Coverage Looks Like
Every quality agreement covers the basics: GMP compliance, regulatory responsibilities, audit rights, and release procedures. Those are table stakes. What separates a strong quality agreement from a weak one is how well it addresses the operational gray areas that create the most friction in practice.
Deviation and CAPA management is a big one. The agreement should define not just that deviations will be investigated, but the expected timelines for investigation and closure, the criteria for when a deviation gets escalated to the sponsor, and how corrective actions are tracked and verified. Without this, you end up in a cycle of chasing your CMO for updates on open investigations with no agreed-upon framework to point to.
Change control is another area where vague language creates real problems. Your quality agreement should clearly delineate which changes require sponsor notification, which require sponsor approval, and which the CMO can implement unilaterally. That distinction matters enormously. A CMO that makes a process change without your knowledge, even a well-intentioned one, can create regulatory complications that take months to resolve.
Communication protocols deserve more attention than they typically get. How are issues communicated? Who are the designated contacts on each side? What's the expected response time for critical notifications versus routine ones? These details feel administrative until the moment a significant quality event happens on a Friday afternoon and nobody can reach the right person.
Annual product reviews, complaint handling, recall procedures, supplier qualification for critical raw materials. These are all areas where a boilerplate quality agreement will say something generic and a thoughtful one will say something specific enough to actually guide decision-making when it matters.
Your Program Will Change. Your Quality Agreement Should Too.
Here's the other mistake that's just as common and arguably more damaging over time: signing a quality agreement at the start of a relationship and never revisiting it.
Programs evolve. A Phase I clinical program has fundamentally different quality requirements than a commercial product. The batch sizes change. The regulatory scrutiny increases. The number of downstream partners in your supply chain grows. The quality agreement you signed when you were manufacturing a few clinical batches a year may not adequately cover the reality of commercial-scale production with ongoing supply commitments.
I've seen companies discover this the hard way, usually when something goes wrong and they go back to the quality agreement only to find that it doesn't address the situation they're in. The process that was fine for clinical scale doesn't have adequate controls for commercial. The communication cadence that worked when there was one batch a quarter isn't sufficient when there are monthly campaigns. The deviation timelines that were loosely defined are now creating real downstream impacts on supply availability.
Building in a regular review cycle for your quality agreements, whether annually or at key program milestones like the transition from clinical to commercial, ensures the document stays current with the reality of the relationship. It's a small investment of time that prevents significant operational and regulatory exposure.
The Conversation Worth Having Now
If you're about to enter a CMO relationship, resist the temptation to sign the CMO's standard template without meaningful negotiation. Their template is written to protect their interests. Your job is to make sure it also protects yours, and more importantly, that it creates a shared operational framework that will serve both parties when the inevitable challenges arise.
If you already have CMO relationships in place, it's worth pulling your quality agreements out and reading them with fresh eyes. Ask yourself whether they reflect the current state of your program. Ask whether the people managing the relationship day to day know what's in them. Ask whether the document would actually help you navigate a serious quality event, or whether you'd be starting from scratch.
The quality agreement is one of those documents that feels routine until it isn't. Getting it right, and keeping it current, is one of the simplest ways to strengthen your CMO relationships and protect your supply chain.
Verant Consulting Group helps biotech companies build and manage CMO relationships that hold up under pressure, from quality agreements and governance frameworks to day-to-day operational oversight. Let's talk about how your outsourcing partnerships are set up.